Original Investigation  Duration of Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: The ICECAP Randomized Clinical Trial William J. Meurer, Sharon D. Yeatts, Romergryko G. Geocadin, et al JAMA Published Online: August 5, 2026 doi: 10.1001/jama.2026.10247 Key Points Question  In comatose survivors of out-of-hospital cardiac arrest treated with therapeutic hypothermia at 33 °C, what duration of cooling maximizes neurological re...

Articles The impact of artificial intelligence-driven decision support on uncertain antimicrobial prescribing: a randomised, multimethod study William J Bolton, Richard Wilson, Mark Gilchrist, et al Lancet Digital Health 2025; 7: 100912 https://doi.org/10.1016/j.landig.2025.100912 Summary Background Challenges exist when translating artificial intelligence (AI)-driven clinical decision support systems (CDSSs) from research into health-care settings, p...

JAMA Clinical Guidelines Synopsis  Perioperative Cardiovascular Medication Management for Noncardiac Surgery David E. Winchester, Jeet J. Mehta, Jason T. Alexander JAMA 2026;335;(19):1717-1718. doi:10.1001/jama.2026.0067 Guideline title 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery Release date September 24, 2024 Prior version 2014 Developers and funding sources&...

Broad-Spectrum Targeted Next-Generation Sequencing In ICU Thu, 9 Apr 2026 A recent commentary by Tseng et al. examines the clinical utility and practical challenges of implementing targeted next-generation sequencing (tNGS) for diagnosing severe pneumonia in ICU settings. While tNGS has demonstrated superior analytical sensitivity compared with conventional microbiological tests (CMTs), its real-world clinical value remains uncertain, particularly in t...

EDITORIAL Price of Protection — Microaxial Flow Pump in High-Risk PCI Brahmajee K. Nallamothu, Brett L. Wanamaker N Engl J Med 2026;394:1855-1856 DOI: 10.1056/NEJMe2602727 In the catheterization laboratory, the most consequential decisions are frequently not about whether to treat, but rather about how far to extend treatment. Nowhere is that tension more apparent than in high-risk percutaneous coronary intervention (PCI). In these cases, the margin between...

ORIGINAL ARTICLE A Phase 3 Trial of Brepocitinib in Dermatomyositis Ruth Ann Vleugels, Julie J. Paik, Iazsmin Bauer Ventura, et al N Engl J Med 2026;394:1883-1893 DOI: 10.1056/NEJMoa2503531 Abstract BACKGROUND Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. METHODS In this phase 3, double-blind, randomized, place...

PERSPECTIVE Can AI Say “I Don’t Know”? Andrea Sikora, Leo A. Celi, Raja-Elie E. Abdulnour N Engl J Med 2026;394:1873-1875 DOI: 10.1056/NEJMp2517624 I will not be ashamed to say “I know not.” — Hippocratic Oath A first-year resident is asked, “What explains the patient’s rising creatinine?” She pauses. “I don’t know ….” The team reviews the patient’s medications and risk factors and chooses a cautious plan involving chec...

Vasoactive Medications and Microcirculation in Septic Shock In Sepsis Thu, 9 Apr 2026 A new review examines the effects of vasoactive medications on the microcirculation in septic shock to synthesise current knowledge and identify gaps in evidence. Sepsis remains a leading cause of inpatient mortality, with rates approaching 30%, and although management strategies focus on restoring macrohaemodynamic parameters such as mean arterial pressure (MAP) and ...

Invited Commentary  Exchange Transfusion for Severe Babesiosis—Insights From a Multicenter Retrospective Analysis Eric A. Meyerowitz, Johanna P. Daily JAMA Intern Med 2026;186;(5):607-608. doi:10.1001/jamainternmed.2026.0252 Babesia microti is a tickborne intraerythrocytic parasite reported in at least 24 states across the US, with 1827 cases reported in 2020.1 Rising cases have been attributed to climate and weather changes across the country. Severe bab...

ORIGINAL ARTICLE Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts Frederick G. Hayden, Masaharu Shinkai, Tristan W. Clark, et al N Engl J Med 2026;394:1905-1915 Abstract BACKGROUND Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously...